Teva Pharmaceutical Industries
- Country
- 🇮🇱Israel
- Ownership
- -
- Employees
- 37.8K
- Market Cap
- $21.2B
- Introduction
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Clinical Trials
139
Trial Phases
3 Phases
Drug Approvals
8
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (78 trials with phase data)• Click on a phase to view related trials
A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02092077
- Locations
- 🇧🇾
Teva Investigational Site 68016, Minsk, Belarus
🇧🇬Teva Investigational Site 59060, Varna, Bulgaria
🇬🇪Teva Investigational Site 81022, Tbilisi, Georgia
TL011 in Severe, Active Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT01123070
- Locations
- 🇨🇿
Teva Investigational Site 5428, Plzen, Czechia
🇨🇿Teva Investigational Site 5426, Prague 2, Czechia
🇨🇿Teva Investigational Site 5429, Uherske Hradiste, Czechia
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 257
- Registration Number
- NCT00745615
- Locations
- 🇨🇿
Teva Investigational Site 382, Hradec Kralove 3, Czechia
🇨🇿Teva Investigational Site 380, Praha 2, Czechia
🇨🇿Teva Investigational Site 384, Praha 5- Motol, Czechia
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: 40 mg glatiramer acetateDrug: Placebo
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT00326625
- Locations
- 🇧🇪
Teva Benelux, Leuven, Belgium
🇫🇷Teva France, Paris, France
🇩🇪Teva Germany, Morfelden-Walldorf, Germany
News
Federal Circuit Rules "Clinically Proven Effective" Claims Cannot Rescue Anticipated Drug Methods from Prior Art
The Federal Circuit held that Bayer's patent claims for rivaroxaban and aspirin combination therapy were unpatentable despite including "clinically proven effective" language, ruling this limitation was functionally unrelated to the actual treatment method.
Teva Receives FDA Approval for Generic Saxenda, Targeting $165 Million Weight Management Market
Teva Pharmaceutical Industries announced FDA approval and U.S. launch of its generic version of Saxenda (liraglutide injection) in late August 2025, targeting a branded product with annual sales of $165 million.
FDA Approves AJOVY as First CGRP Antagonist for Pediatric Migraine Prevention
Teva Pharmaceutical Industries received FDA approval for AJOVY as the first CGRP antagonist indicated for preventive treatment of episodic migraine in children and adolescents aged 6-17 weighing at least 45 kilograms.
German Federal Patent Court Revokes Key Xarelto Patent, Opening Door for Generic Competition
The German Federal Patent Court revoked Bayer's crucial Xarelto patent EP 1 845 961 due to lack of inventive step, contradicting its earlier 2024 opinion that assumed the patent's validity.
Leveragen and Propeller Bio Form Strategic Partnership to Advance Next-Generation Antibody Discovery Platform
Leveragen, a Boston-based biotech company, has announced a strategic collaboration with newly launched Propeller Bio to advance antibody and protein-based therapeutics development.
Vor Bio Appoints Telitacicept Development Expert Dr. Qing Zuraw as Chief Development Officer
Vor Bio has appointed Dr. Qing Zuraw as Chief Development Officer, bringing over 25 years of experience in autoimmune disease clinical development.
J&J Wins Federal Circuit Appeal, Preserves Invega Sustenna Patent Protection Until 2031
Johnson & Johnson successfully defended its Invega Sustenna schizophrenia drug patent against appeals from Teva and Viatris, maintaining market exclusivity until 2031.
Biocon Races to Launch First Generic Semaglutide in Canada as Wegovy Patents Expire
Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.
Teva Partners with Formycon to Commercialize Stelara Biosimilar Fymskina in Germany
Formycon AG has entered into a distribution agreement with Teva's subsidiary Ratiopharm for the semi-exclusive commercialization of its Stelara biosimilar FYB202, branded as Fymskina, in Germany.
Digital Inhaler Technology Shows Promise for Early COPD Exacerbation Detection
Digital inhalers can detect significant physiologic changes up to two weeks before COPD exacerbations occur, potentially enabling earlier clinical intervention.